# A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

> **NCT06916091** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Eloralintide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06916091
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-21
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-09-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916091, "A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06916091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*